• Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (drugs.com)
  • Prior therapy should have included an anthracycline and a taxane. (eisai.com)
  • courses repeated at 28-day intervals) and VAC (vincristine 1.4 mg/m 2 every 3 weeks, anthracycline 30 mg/m 2 every 3 weeks, cyclophosphamide 400 mg/m 2 every 3 weeks) in patients with advanced metastatic breast cancer. (karger.com)
  • In patients with breast cancer receiving adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D), we evaluated the impact of chemotherapy total cumulative dose (TCD), and early (FEC) versus late (D only) dose reductions, on survival outcomes. (jnccn.org)
  • Landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. (jnccn.org)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • This study sought to retrospectively characterize outcomes for patients with node-negative and node-positive breast cancer receiving adjuvant trastuzumab in combination with docetaxel/cyclophosphamide (DCH), docetaxel/carboplatin/trastuzumab (TCH), or fluorouracil/epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (FEC-DH) chemotherapy in Alberta, Canada, from 2007 through 2014. (jnccn.org)
  • The only systemic therapy currently available for patients with TNBC is adjuvant chemotherapy with anthracyclines (e.g., doxorubicin), taxanes (e.g., paclitaxel), or cyclophosphamide. (utaustinportugal.org)
  • vitamin D3 levels can be reduced under chemotherapy , e.g. fall with anthracyclines, cyclophosphamide and taxanes, as these are pregnane X receptor ligands and so trigger an enzyme induction of 24-hydroxylase the increased degradation of 25 (OH) D and 1,25 (OH) D! (vitamindwiki.com)
  • Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
  • Background Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breast cancer to reduce the risk of cancer recurrence. (mendeley.com)
  • Patients at high risk for recurrence should be evaluated for adjuvant treatment with CDK4/6 inhibitors. (medscape.com)
  • Postmenopausal women at high risk for recurrence can be evaluated for adjuvant treatment with a bisphosphonate. (medscape.com)
  • Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. (nih.gov)
  • or for adjuvant treatment of patients with HER2-positive EBC at high risk of recurrence. (empr.com)
  • Adjuvant: give every 3 weeks for a total of 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity. (empr.com)
  • Thirty-one patients with Stage I or II uterine sarcomas, referred to our center for adjuvant chemotherapy, received anthracycline-based regimens. (imrpress.com)
  • Seventeen (54.8%) patients received ifosfamide, etoposide and epirubicin, six (19.4%) were treated with doxorubicin and carboplatin, three (9.6%) were administered doxorubicin and ifosfamide, while five (16.1 %) patients received various anthracycline-based regimens. (imrpress.com)
  • Neratinib: A tyrosine kinase inhibitor approved for the extended adjuvant treatment of patients with early-stage Her2Neu-positive breast cancer, following adjuvant trastuzumab-based therapy. (medscape.com)
  • The target of anthracycline drugs is Topoisomerase II, and its location in regards to the Her-2 gene on the chromosome is what allows the anthracycline drug to be effective in patients with heavy expression of the Her-2/neu protein. (wikipedia.org)
  • The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens. (herceptin.com)
  • Patients with invasive breast cancer that is ER+ or progesterone receptor positive (PR+) should be considered for adjuvant endocrine therapy with tamoxifen or aromatase inhibitors (AIs). (medscape.com)
  • PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs. (mpg.de)
  • With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. (carcinogenesis.com)
  • We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. (nih.gov)
  • Patients were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles. (nih.gov)
  • Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. (curehunter.com)
  • Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. (curehunter.com)
  • Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. (curehunter.com)
  • Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
  • Comparative real-world outcomes for patients with HER2-positive (HER2+) breast cancer receiving adjuvant trastuzumab outside of clinical trials are lacking. (jnccn.org)
  • Unless contraindicated, patients had to have received an anthracycline and/or a taxane in the neoadjuvant, adjuvant, and/or metastatic treatment setting. (ahdbonline.com)
  • Overall, 91% of patients in the talazoparib arm received previous taxane therapy, and 85% received an anthracycline. (ahdbonline.com)
  • Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting. (onclive.com)
  • There were] nearly 5000 patients, and they had the choice of an anthracycline-taxane-based chemotherapy backbone with trastuzumab or the docetaxel-carboplatin regimen with trastuzumab. (onclive.com)
  • Gemcitabine HCI for Injection is also indicated in combination with Paclitaxel for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. (fresenius-kabi.com)
  • Santini D, Galluzzo S, Vincenzi B. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. (vitamindwiki.com)
  • Patients and methods proportion of the patients will recur despite treatment with adjuvant polychemotherapy. (lu.se)
  • We also have 1 year of olaparib in the adjuvant setting for patients with germline BRCA mutation and high-risk breast features. (medscape.com)
  • For their study, they assigned patients with early-stage (T0) KS to combined antiretroviral (cART) therapy alone, and those with advanced-stage (T1) KS to cART plus liposomal anthracycline chemotherapy. (medscape.com)
  • Combination chemotherapy regimens are standard recommendations in the adjuvant setting. (medscape.com)
  • We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • Including anthracycline drugs as part of chemotherapy regimens produces a small but statistically significant survival advantage over regimens that do not contain anthracyclines. (pharmexec.com)
  • Today, anthracycline and taxane-based treatment strategies are commonly used in clinical routine, since these regimens have been shown to be superior compared to other standard chemotherapies. (justia.com)
  • Objectives To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy. (mendeley.com)
  • Adjuvant therapy for breast cancer is designed to treat any potential micrometastatic disease, or breast cancer cells that have escaped the breast and regional lymph nodes but have not yet established an identifiable metastasis. (medscape.com)
  • Tamoxifen has been the gold standard adjuvant hormonetherapy for the treatment of postmenopausal women with hormone-receptor-positive early BC for many years, but the third-generation aromatase inhibitors (letrozole, anastrozole, and exemestane) are now recommended as the preferred therapy. (isciii.es)
  • One of Pritchard's self-proclaimed "eureka" moments was in a clinical trial concerning the use of the drug Letrozole as an adjuvant therapy in postmenopausal women who had taken tamoxifen for five years as a primary breast cancer treatment. (wikipedia.org)
  • 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
  • Monitor and assess LVEF every 6 months for ≥2yrs after therapy (if adjuvant). (empr.com)
  • Five years of tamoxifen is currently the standard adjuvant hormonal therapy. (pharmexec.com)
  • Some factors that are considered when selecting the specific agent include what they received as adjuvant therapy and their disease-free interval. (cancertherapyadvisor.com)
  • Assess the antitumor activity of pemetrexed disodium in combination with gemcitabine in the treatment of women with metastatic breast cancer who have received an anthracycline and a taxane in the adjuvant and/or metastatic setting and no more than 1 chemotherapy regimen for metastatic disease (unless these were a taxane and anthracycline). (knowcancer.com)
  • This threshold, in addition to early versus late dose reductions, are poorly defined for third-generation anthracycline/taxane-based chemotherapy. (jnccn.org)
  • Start on Day 1 of the first taxane-containing cycle (if standard anthracycline- and/or taxane-based chemotherapy is part of regimen). (empr.com)
  • For T1c, adjuvant trastuzumab-based chemotherapy is considered standard. (onclive.com)
  • Another study looked at the effects of adjuvant therapies like Letrozole in women of different ages, both premenopausal and postmenopausal. (wikipedia.org)
  • Effect of vitamin D supplementation on serum 25- hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. (vitamindwiki.com)
  • Selection criteria Randomised controlled trials comparing administering a taxane prior to an anthracycline with taxane following anthracycline to people with early breast cancer receiving chemotherapy. (mendeley.com)
  • MMM is an effective, well-tolerated regimen for advanced breast cancer, with toxicity similar to that of CMF and less than that of an anthracycline-contain-ing regimen. (karger.com)
  • The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
  • Anthracyclines tend to be administered first as they were established before taxanes for treatment of early breast cancer. (mendeley.com)
  • Main results There were 1415 participants in five neoadjuvant studies and 280 participants in four adjuvant studies involving five treatment comparisons. (mendeley.com)
  • Adjuvant treatment of operable breast cancer. (isciii.es)
  • Anthracyclines and taxanes are very important in the adjuvant treatment of BC. (isciii.es)
  • Treatment of early-stage breast cancer with adjuvant chemotherapy has improved survival. (jnccn.org)
  • A common adjuvant treatment, for example, is a single-agent anthracycline. (cancertherapyadvisor.com)
  • In order to achieve a more effec- were recommended postoperative radiation and adjuvant tive and individualised chemotherapeutic treatment of breast chemotherapy. (lu.se)
  • Several large clinical trials demonstrated that the addition of taxanes to anthracycline-based treatment strategies results in an improved clinical outcome (Martin et al. (justia.com)
  • Ki67-a well-known cell proliferation marker-has been described to predict the benefit from adjuvant taxane-based treatment in the PACS01 trial (Penault-Llorca, J C O, 2008). (justia.com)
  • As a result, Dr Tolaney said that "we don't use a lot of anthracyclines in the metastatic setting, but sometimes I will use liposomal doxorubicin in a patient who didn't have an adjuvant anthracycline. (cancertherapyadvisor.com)
  • Of those with advanced-stage KS, 140 (84%) were treated with cART plus liposomal anthracycline chemotherapy, 14 (8%) were treated with cART alone, 9 (5%) were treated with cART and radiotherapy for localized ulcerating tumors, and 3 (2%) were treated with cART plus complete excision. (medscape.com)
  • A few years later, we finally saw the approval of pertuzumab in the adjuvant setting. (onclive.com)
  • Most of us will use the APT [adjuvant paclitaxel-trastuzumab] regimen with weekly paclitaxel and a year of trastuzumab. (onclive.com)
  • Clinical trials over the past ten years have contributed an enormous amount of new information about adjuvant therapies,' said panel chair Patricia Eifel, professor of radiation oncology at M.D. Anderson Cancer Center in Houston. (pharmexec.com)
  • The patient received adjuvant third-generation chemotherapy with a taxane and an anthracycline, followed by radiotherapy to the breast, supraclavicular fossa and axilla. (cmaj.ca)
  • Furthermore, the overall survival benefit found for adjuvant chemotherapy may have been confounded by the administration of postoperative radiotherapy. (bvsalud.org)
  • Patient who undergo upfront surgery can qualify for adjuvant chemotherapy based on gene expression profiling such as the Oncotype DX, MammaPrint, or Prosigna. (medscape.com)
  • Trastuzumab in combination with adjuvant chemotherapy has changed the natural history of early Her-2 positive BC. (isciii.es)
  • The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. (carcinogenesis.com)
  • Breast cancer is a heterogeneous disease with a large variabil- survival after adjuvant polychemotherapy was 10% (from ity in clinical outcome. (lu.se)
  • Standard practice is to administer anthracycline-based chemotherapy followed by a taxane. (mendeley.com)
  • APHINITY was a large, very standard adjuvant study. (onclive.com)
  • Pritchard has postulated that women with breast cancer and high levels of the Her-2/neu protein are predisposed to respond more favorably to anthracycline-containing chemotherapy drugs than women with normal Her-2/neu levels. (wikipedia.org)
  • Pritchard demonstrated that women with high levels of Her-2 expression have a better response to the anthracycline containing drugs in a clinical trial. (wikipedia.org)
  • For chemotherapy drugs, one of the best characterized resistance mechanisms is overexpression of MDR1 , a cell membrane transporter that causes efflux of certain drugs (eg, vinca alkaloids, taxanes, anthracyclines). (msdmanuals.com)
  • the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and Orlando Health University of Florida Health Cancer Center, Orlando (E.P.M. (nih.gov)
  • Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas. (imrpress.com)
  • In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)
  • Women with stage I-III, hormone receptor-positive/negative, HER2-negative breast cancer treated with adjuvant FEC-D chemotherapy from 2007 through 2014 in Alberta, Canada, were included. (jnccn.org)